1998
Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products
Wang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 7643-7647. PMID: 9636203, PMCID: PMC22709, DOI: 10.1073/pnas.95.13.7643.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsLow-density lipoproteinGlycation end productsLDL receptorAGE modificationAbnormal lipoprotein profilesGlycation of LDLInability of LDLPrevious immunochemical studiesRenal failureLipoprotein profileTime-dependent decreaseCardiovascular diseaseApolipoprotein BAdvanced glycationDensity lipoproteinReceptor-binding siteEnd productsImmunochemical studiesEpitopesGlycationCellular uptakeMultiple sitesPatientsDiabetes
1996
Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis
Bucala R. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis. Nephrology Dialysis Transplantation 1996, 11: 17-19. PMID: 9044301, DOI: 10.1093/ndt/11.supp5.17.Peer-Reviewed Original ResearchConceptsLDL receptorAGE modificationApolipoprotein BAdvanced glycosylationHuman fibroblast LDL receptorsAGE-modified formAGE-specific antibodiesRegion of apoBNon-diabetic individualsFibroblast LDL receptorLDL receptor binding siteRenal insufficiencyDiabetes mellitusDiabetic patientsElevated LDLAGE-LDLLipoprotein clearanceReceptor binding sitesHuman LDL receptorGeneral populationPlasma clearance kineticsTransgenic miceLDLAGE formationClearance kinetics
1995
Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *
Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor *. Journal Of Biological Chemistry 1995, 270: 10828-10832. PMID: 7738020, DOI: 10.1074/jbc.270.18.10828.Peer-Reviewed Original ResearchConceptsLow-density lipoproteinAGE-modified formAdvanced glycosylation end productsLDL receptorApolipoprotein BHuman fibroblast LDL receptorsAGE-specific antibodiesApolipoprotein B modificationDiabetic vascular diseaseLow-density lipoprotein receptorGlycosylation end productsDensity lipoprotein receptorFibroblast LDL receptorMajor siteAGE immunoreactivityRenal insufficiencyGlucose-derived Amadori productsVascular diseasePlasma clearance kineticsDensity lipoproteinLipoprotein receptorAGE formationClearance kineticsAGE modificationPredominant siteAdvanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition
Bucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsDiabetic renal diseaseNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesTissue LDL receptorsForms of LDLRenal functionRenal diseaseLDL levelsTherapeutic modalitiesVascular permeabilityPathophysiological significanceAdvanced glycosylationLipoprotein depositionPharmacological inhibitionLDL receptorClinical measurementsNitric oxideEndothelial cellsMarked increaseMiddle moleculesLDLToxic effectsEndproducts